Boji Medical

Boji Medical (博济医药) is a Chinese contract research organization (CRO) operating in the pharmaceutical and biotechnology services sector. The company provides outsourced research and development support to drug developers, a category commonly referred to as CRO or CDMO services. Its official web presence is at boji-pharm.com. The brand is associated with the broader life-sciences tools and services industry in China, where demand for outsourced clinical and preclinical development has grown alongside the country's expanding pharmaceutical market. As a CRO, Boji Medical's business model centers on offering specialized expertise and infrastructure to pharmaceutical and biotech clients that choose to externalize parts of their development programs rather than build all capabilities in-house. The available evidence identifies the entity as a CRO brand but does not provide verified details on its founding, ownership, leadership, or specific service lines. This dossier therefore remains limited to the confirmed identity and sector classification, and further verified information would be needed to expand the entry.

The available evidence identifies Boji Medical as a CRO brand but does not include verified historical details such as founding date, founders, ownership changes, or corporate milestones. A full history cannot be written without additional sourced information. The company operates in China's contract research sector, a field that has expanded as Chinese and multinational pharmaceutical developers increasingly outsource clinical and preclinical work. Further verified facts would be required to document its specific trajectory.

Product categories. Contract research services

• Unconfirmed

  Great Bay Bio and Boji Medical agree to develop GBB101[1]大湾生物与博济医药合作开发 GBB101finance.sina.com.cn

  Reported: 2019-10-14

  Great Bay Bio and Boji Medical signed a bilateral agreement to jointly develop GBB101, a long-acting biologic injection for anemia associated with impaired kidney function. The agreement establishes a clinical research partnership for the coming years and provides for a joint team and shared development results.

1. 1大湾生物与博济医药合作开发 GBB101finance.sina.com.cn